CASE COMMUNICATION
IMAJ | volume 25
Journal 6, June 2023
pages: 445-446
Loss of Function RET Gene Variant and Cancer: Co-occurrence or an Association?
1 Oncology Institute, Sheba Medical Center, Tel Hashomer, Israel
2 Levy Gertner Oncogenetics Unit, Sheba Medical Center, Tel Hashomer, Israel
3 Meirav High Risk Clinic, Sheba Medical Center, Tel Hashomer, Israel
4 Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
Summary
Germline pathogenic variants (PVs) in the RET proto-oncogene (OMIM 164761) are associated with a diverse phenotype based on the type of PV. Gain-of-function (GOF) PVs are associated with the highly penetrant multiple endocrine neoplasia type 2 (MEN2-OMIM 171400), which are hallmarked by an increased risk for developing medullary thyroid cancer (MTC), pheochromocytoma, and parathyroid adenomas. Loss-of-function (LOF) RET PVs are associated with incompletely penetrant Hirschsprung's disease (HSCR OMIM 142623), which are pathologically characterized by the absence of enteric ganglia affecting the distal colon and clinically manifest as neonatal intestinal obstruction. Despite anecdotal reports of familial clustering of neoplasms in HSCR families, mostly MEN2-associated tumors [1,2], HSCR is not considered to be associated with an increased risk for developing cancer [3]. We report on a family with an unusual multigenerational solid tumor phenotype and severe HSCR phenotype with a LOF RET PV.